Use of neoadjuvant paclitaxel in breast angiosarcoma—Impact on surgical resection and response rates

Abstract

ObjectiveBreast angiosarcoma is a tumor that can arise as a primary breast tumor or in association with prior radiation therapy. Angiosarcomas are uniquely sensitive to paclitaxel. This study evaluated the impact neoadjuvant paclitaxel (NAC) therapy has on surgical outcomes, tumor recurrence, and survival in breast angiosarcomas.MethodsPatients with angiosarcoma of the breast, either primary or radiation‐associated, were identified from a prospective institutional database. Patients receiving NAC were compared to those treated with upfront surgery. Clinical and pathological variables were compared using Student's t‐test or Fisher's exact test, differences in survival were calculated using Kaplan–Meier methods.ResultsTwenty‐four patients with angiosarcoma of the breast were identified, 10 with primary angiosarcoma and 14 with radiation‐associated angiosarcoma. Twelve patients received NAC, 6 of each with primary angiosarcoma or radiation‐associated angiosarcoma. Of these 12 patients, 11 had a margin negative resection (91%) of which, nine had a complete pathological response on surgical pathology. Of the 12 surgery‐first patients, four (n = 4/12, 33%) had positive surgical margins, two of the four underwent reoperation. With a median follow‐up of 16 months, four NAC patients had recurrence (33%) compared to six patients in the surgery‐first group (58%) (p = 0.41). While not statistically significant, NAC patients had a 33% less risk of recurring compared to surgery‐first patients ([hazard ratio =0.67 (95% confidence interval 0.16–2.72; p = 0.6]).ConclusionNAC for breast angiosarcoma may be associated with high rates of complete pathological response and margin‐negative resection. However, this did not impact overall survival. Future prospective control studies and longer follow‐up periods are warranted to understand the impact on recurrence and survival.